New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Eli Lilly and Company

LLY

Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.

Revenue
+38.6%
EPS
+16.3%
Free cash flow
+21.8%
Total debt
+15.0%

Quarter to September 2026, against a year earlier

1,355.42 3.77 +0.28%
Market cap
$1.27T
P/E
43.9×
Fwd P/E FY26e
42.2×
Dividend yield
0.51%
F-score
7/9
ROIC
26.4%
Net debt / EBITDA
1.2×
Payout ratio
0.2×

Eli Lilly and Company (LLY) EV/FCF

Alert me on EV/FCF

As of Nov 19, 2026, Eli Lilly and Company (LLY) trades at a EV/FCF of 57.4×. Over the past ten years it has ranged from 16.2× (February 2018) to 534× (June 2024); the current reading is higher than 72% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 89.5× (26.10%)
FY2024 121× (45.88%)
FY2023 224× 277.89%
FY2022 59.2× 45.26%
FY2021 40.8× 35.42%
FY2020 30.1× (6.35%)
FY2019 32.1× 25.74%
FY2018 25.6× 38.98%
FY2017 18.4× (2.79%)
FY2016 18.9× (51.17%)

Quarterly newest first

Period EV/FCF Change
Sep 2026 49.5× (9.67%)
Jun 2026 54.7× (10.57%)
Mar 2026 61.2× (31.58%)
Dec 2025 89.5× 42.35%
43 more quarters

Against its own ten years

Low 16.2× High 534×
Ten-year median 36.4×
Current reading's percentile 69

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on LLY